Released May 7, 2025, after the close
10-Q filed May 7, 2025, 37 days after period end · 0001641172-25-009044
Q1 2025 · 10-Q
Revenue—
Net Income-$8.20M-$8.20M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$57.76-$57.76 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$2,730,000N/M
Operating Cash Flow-$2,065,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | — | $47.00K | $0.00 | — |
| Net Income | -$8.20M | -$6.65M | -$5.42M | -$9.38M |
| EPS Diluted | -$57.76 | -$1.23 | -$1.06 | -$3.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR